Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties
暂无分享,去创建一个
Thomas R. Miller | Gerard B. Fox | Jill M. Wetter | J. Sullivan | G. Fox | A. Hancock | K. Marsh | Marlon D. Cowart | Liping Pan | Youssef L. Bennani | Kennan Marsh | Chae Hee Kang | T. Esbenshade | David G. Witte | Arthur A. Hancock | Timothy A. Esbenshade | Kathleen M. Krueger | Lynne I. Denny | Betty B. Yao | Liping Pan | Jill Wetter | James P. Sullivan | M. Cowart | T. Miller | K. Krueger | D. Witte | C. Kang | Y. Bennani | B. Yao | L. Denny
[1] S. L. Yates,et al. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. , 1998, European journal of pharmacology.
[2] Genomic organization and characterization of splice variants of the human histamine H3 receptor. , 2001 .
[3] Michael Williams,et al. Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects , 2003, Journal of Pharmacology and Experimental Therapeutics.
[4] T. Lovenberg,et al. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. , 2001, The Journal of pharmacology and experimental therapeutics.
[5] J. Schwartz,et al. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.
[6] B. McMillen. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission , 2005, Journal of Neural Transmission.
[7] A. Hancock,et al. Species-related pharmacological heterogeneity of histamine H(3) receptors. , 2001, European journal of pharmacology.
[8] R. Leurs,et al. Therapeutic potential of histamine H3 receptor agonists and antagonists. , 1998, Trends in pharmacological sciences.
[9] M. Giovannini,et al. H3 receptor modulation of the release of neurotransmitters in vivo , 1998 .
[10] M. Williams,et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. , 2004, Biochemical pharmacology.
[11] J. Schwartz,et al. Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. , 2003, Journal of neural transmission. Supplementum.
[12] M. Jackson,et al. Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.
[13] W. Chai,et al. Non-imidazole heterocyclic histamine H3 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[14] A. Hancock,et al. Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity , 2003, Neuropharmacology.
[15] A. Hancock,et al. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. , 2004, Mini reviews in medicinal chemistry.
[16] A. Hancock,et al. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. , 2003, Life sciences.
[17] H. Schild. pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM , 1997, British journal of pharmacology and chemotherapy.
[18] C. Dvorak,et al. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. , 2003, Journal of medicinal chemistry.
[19] S. M. Knudsen,et al. 1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists. , 2004, Journal of medicinal chemistry.
[20] B. Conklin,et al. Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. , 1999, Analytical biochemistry.
[21] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[22] Holger Stark,et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.
[23] M. Williams,et al. Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization , 2003, Journal of Pharmacology and Experimental Therapeutics.
[24] J. Boutin,et al. Genomic organization and characterization of splice variants of the human histamine H 3 receptor , 2022 .
[25] Min Zhang,et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.
[26] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[27] R. Leurs,et al. [3H]‐thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex , 1996, British journal of pharmacology.
[28] R. Leurs,et al. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. , 2001, Molecular pharmacology.
[29] J. Black,et al. Characterization of the binding of [3H]‐clobenpropit to histamine H3‐receptors in guinea‐pig cerebral cortex membranes , 1999, British journal of pharmacology.
[30] M. Jackson,et al. Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.
[31] M. Decker,et al. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup , 2002, Behavioural Brain Research.
[32] P. Leff,et al. Further concerns over Cheng-Prusoff analysis. , 1993, Trends in pharmacological sciences.
[33] G. Coruzzi,et al. The Histamine H3 Receptor , 2000 .
[34] A. Hancock,et al. A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans. , 2004, Bioorganic & medicinal chemistry letters.
[35] A. Hancock,et al. Characterization of Histaminergic Receptors , 2000 .
[36] J. Witkin,et al. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.
[37] M. Erlander,et al. Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. , 2000, The Journal of pharmacology and experimental therapeutics.
[38] C R Ganellin,et al. Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.
[39] J. Schwartz,et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. , 1998, The Journal of pharmacology and experimental therapeutics.
[40] S. Hastrup,et al. Characteristics of recombinantly expressed rat and human histamine H3 receptors. , 2002, European journal of pharmacology.
[41] J. Barnes,et al. Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. , 1993, European journal of pharmacology.
[42] J. Schwartz,et al. Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.